Sagimet Biosciences (SGMT) Long-Term Investments (2024 - 2025)
Sagimet Biosciences (SGMT) recorded quarterly Long-Term Investments of $8.8 million in Q3 2025, down 12.46% quarter-over-quarter from $10.1 million in Q2 2025, and down 49.6% on a YoY basis from $17.5 million in Q3 2024.
Sagimet Biosciences (SGMT) Long-Term Investments (2024 - 2025) Analysis & Trends
Sagimet Biosciences' Long-Term Investments history runs 2 years deep, the most recent figure standing at $8.8 million for Q3 2025.
- In Q3 2025, Long-Term Investments fell 49.6% year-over-year to $8.8 million; the TTM figure through Sep 2025 stood at $8.8 million (down 49.6% YoY), while the FY2024 annual figure was $7.4 million, changed N/A from the prior year.
- Long-Term Investments was $8.8 million for Q3 2025 at Sagimet Biosciences, down from $10.1 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $22.1 million in Q2 2024 to a low of $7.4 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 5.17 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 5.75 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Sagimet Biosciences | 211.96 Mn | 211.96 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 8.81 Mn |
| Jun 30, 2025 | 10.06 Mn |
| Dec 31, 2024 | 7.41 Mn |
| Sep 30, 2024 | 17.47 Mn |
| Jun 30, 2024 | 22.12 Mn |